Guggenheim raises target for Danaher stock from USD 200.00 to USD 250.00
Published on 10/05/2026 at 09:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Guggenheim raised its Danaher stock target from USD 200.00 to USD 250.00 on October 1, 2026, while keeping a Buy rating, according to Markets Insider. The move gives Danaher a fresh analyst catalyst before its next operating update.
Leadership changes on October 1
Julie Sawyer Montgomery assumed the roles of President and Chief Executive Officer and joined Danaher's board on October 1, 2026. Danaher said Rainer Blair will remain a senior advisor through March 31, 2027, creating a defined handover period for the life sciences and diagnostics group.
The leadership change matters because the company is entering an earnings checkpoint with a new chief executive in place. Danaher operates across biotechnology, diagnostics and life sciences, so execution across several end markets will shape how investors assess the higher target.
Second-quarter figures beat estimates
Danaher reported USD 6.26 billion in revenue for the second quarter of 2026, up 5.50 percent year over year, according to MarketBeat. Reported earnings per share reached USD 1.94 versus a USD 1.85 consensus estimate, a USD 0.09 comparison that supports the more constructive analyst stance.
Standardized financial data show second-quarter revenue of USD 6.265 billion, operating profit of USD 1.127 billion and net income of USD 870.0 million. The operating margin was 18.00 percent, giving investors a clear counterweight to the target increase because revenue growth still has to translate into sustained profitability.
October 21 is the next checkpoint
Danaher scheduled its third-quarter 2026 earnings conference call for October 21, 2026. The company also maintains a quarterly cash dividend of USD 0.40 per share, with the payment scheduled for October 30, 2026.
That calendar leaves the new CEO and the latest operating figures as the key reference points for the next valuation discussion. Danaher's market capitalization was USD 150.5 billion as of October 2, 2026, while its primary-exchange 52-week range was USD 160.93 to USD 242.80.
Danaher stock trades above its prior close
Danaher stock was trading at EUR 191.63 at Lang & Schwarz on October 5, 2026 at 9:46 a.m. CEST, up 0.70 percent versus the prior close of EUR 190.30 on October 2, 2026. The Nasdaq-listed shares were last quoted at USD 214.06 on October 2, 2026 at 4:02 p.m. ET.
The further course of trading is shown by the continuously updated real-time quote of Danaher stock.
Danaher stock facts
- Company: Danaher Corporation
- ISIN: US2358511028
- WKN: 866197
- Ticker: DHR
- Primary exchange: NYSE
- Price Lang & Schwarz as of October 5, 2026, 9:46 a.m. CEST: EUR 191.63
- Change versus prior close: plus 0.70 percent
- Prior close Lang & Schwarz October 2, 2026: EUR 190.30
- Market capitalization: USD 150.5 billion as of October 2, 2026
- 52-week range: USD 160.93-242.80 as of October 2, 2026
- Sector / Industry: Healthcare / Medical Diagnostics and Research
- Index membership: S&P 100
- Next earnings date: October 21, 2026
